Can Gilead's deal with VIR boost its oncology pipeline and growth?
Gilead Sciences, Inc. GILD recently entered into a collaboration and license agreement with Vir Biotechnology, Inc. VIR to ...
Model output · Signal date 2026-10-16
Gilead Sciences, Inc. (GILD) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 5184 stocks scored
Rank correlation · 90D
10.0%
Spearman, 357 dates
Market Cap
$193.67B
large-cap · #2 of 60 peers
Summary
Gilead Sciences, Inc. (GILD) stock forecast summary
On Oct. 16, 2026, GILD is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Gilead Sciences, Inc. is a large-cap company with a market capitalization of $193.67B. It ranks number 2 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Current Ratio of 1.27x is the lowest of the 59 peers that report one.
For GILD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GILD included.
Follow GILD freePrice
GILD price chart and AI forecast
Cross-section · 2026-10-16
How GILD ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Gilead Sciences, Inc. (GILD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | GILD | Rank |
|---|---|---|
| Market Cap | $193.67B | 2/60 |
| P/B Ratio | 16.37x | 8/49 |
| Dividend Yield | 2.10% | – |
| EPS | $-2.66 | – |
| Book Value/Share | $9.54 | – |
| Revenue/Share | $24.56 | – |
| FCF/Share | $10.44 | – |
Profitability & Margins
| Metric | GILD | Rank |
|---|---|---|
| ROE | -27.4% | 21/47 |
| ROA | -6.6% | 16/50 |
| ROIC | -6.5% | 16/53 |
| Gross Margin | 79.6% | 9/24 |
| Operating Margin | -8.2% | 16/40 |
| Net Margin | -10.6% | 16/37 |
| EBT Margin | -6.4% | 16/42 |
| Tax Rate | -65.7% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | GILD | Rank |
|---|---|---|
| Current Ratio | 1.27x | 59/59 |
| Quick Ratio | 1.09x | 28/28 |
| D/E Ratio | 3.18x | 6/53 |
| Financial Leverage | 4.17x | 6/52 |
| Interest Coverage | 1.9x | 13/37 |
| Working Capital | $2.92B | 7/59 |
Cash Flow
| Metric | GILD | Rank |
|---|---|---|
| Operating Cash Flow | $13.55B | 2/57 |
| Free Cash Flow | $12.94B | 2/50 |
| Capital Spending | -$609M | 48/50 |
| OCF Growth YoY | 37.3% | 9/16 |
| FCF Growth YoY | 38.1% | 7/15 |
| FCF/Sales | 42.5% | 4/32 |
| CapEx/Sales | 2.0% | 24/32 |
Operational Efficiency
| Metric | GILD | Rank |
|---|---|---|
| Asset Turnover | 0.62x | 12/36 |
| Receivables Turnover | 6.0x | 12/24 |
| Inventory Turnover | 3.2x | 10/23 |
| Fixed Assets Turnover | 5.2x | 15/37 |
| Days Sales Outstanding | 61 days | 13/24 |
| Days Inventory | 115 days | 14/23 |
| Payables Period | 40 days | 18/26 |
| Cash Conversion Cycle | 136 days | 7/18 |
Income Statement
| Metric | GILD | Rank |
|---|---|---|
| Total Revenue | $30.46B | 2/37 |
| Operating Income | -$2.50B | 53/54 |
| Net Income | -$3.24B | 50/50 |
| R&D Expense | $6.07B | 3/56 |
| SG&A Expense | $6.52B | 2/22 |
| Cost of Goods Sold | $6.22B | 2/26 |
Dividend & Shareholder Information
| Metric | GILD | Rank |
|---|---|---|
| Dividends Per Share | $3.28 | – |
| Shares Outstanding | 1240M | – |
| Net Income Growth | -151.3% | 10/12 |
| EPS Growth | -152.9% | 11/14 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $13.95B | 28.3% of assets |
| Cash & Short-term Investments | $3.18B | 6.4% of assets |
| Accounts Receivable | $5.05B | 10.2% of assets |
| Inventory | $1.95B | 4.0% of assets |
| Total Liabilities | $37.62B | 76.2% of assets |
| Short-term Debt | $10.35B | 21.0% of assets |
Quarterly Financial Reports
GILD quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Gilead Sciences, Inc. (GILD) industry peers
Companies classified under the same SEC industry code as Gilead Sciences, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| AMGN Amgen Inc | ▼ | $233.82B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $521M |
Where GILD sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Gilead Sciences, Inc. (GILD) stock news
Gilead Sciences, Inc. (GILD) is attracting investor attention: Here is what you should know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the ...
FAQ
Gilead Sciences, Inc. (GILD) stock forecast FAQ
What is the Gilead Sciences, Inc. (GILD) stock forecast?
On Oct. 16, 2026, GILD is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Gilead Sciences, Inc. stock predictions?
For GILD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Gilead Sciences, Inc. forecasts updated?
Gilead Sciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Gilead Sciences, Inc.'s industry peers?
60 issuers in our coverage, GILD included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB), Biontech Se (BNTX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.